Park Medi World Limited

Park Medi World Limited (PARKHOSPS) is a small-cap Healthcare company valued at ₹10,196 crore operating in Hospital on the NSE and BSE.

Recent price move

Park Medi World Limited last traded at ₹236.8, modestly up 0.70% on the day.

Recent developments

On 2026-06-30, the company reported its latest quarterly results, showing a significant rise in both revenue and net profit compared to the same period last year. The company has maintained consistent revenue growth over the past five years, with a compound annual growth rate of 17.0%.

Financial performance

The company's business is improving, with annual revenue rising 20.5% and annual net profit growing 27.2%. The latest quarter saw revenue increase 19.2% compared to the same quarter a year earlier, while net profit rose 34.2%, outpacing revenue growth. The net profit margin widened by 0.9 percentage points to 16.3%, and return on capital employed stands at 17.3%.

Valuation multiples

The stock trades at 34.5 times earnings, broadly in line with the Healthcare median of 32.0, 6.03 times book value.

Things to watch

The company has not paid out any dividends despite reporting repeated profits, which may raise concerns about capital returns to shareholders. The stock is currently 11.2% below its 52-week high, indicating a potential pullback from recent levels. The company's debt to equity ratio is low at 0.18, but this does not offset the lack of dividend payouts.

Where it stands

The company has shown strong revenue and profit growth over the past year and quarter, with the net profit margin widening. The stock is trading 11.2% below its 52-week high, and the company has not distributed any dividends to shareholders. The most significant figure is the latest quarter net profit, which rose 34.2% compared to the same quarter a year earlier.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.